Results 21 to 30 of about 12,689 (257)

Method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics [PDF]

Hospital Pharmacology, 2021
Introduction: Key problems when transferring results of pharmacoeconomic studies between countries are: relative infrequency of observational design, utilization of unreliable estimates of input parameters in many of modelling studies, not reporting ...
Janković Slobodan M., Kostić Marina J., Milovanović Jasmina R.   +2 more
doaj   +1 more source

The cost-effectiveness of exercise referral schemes [PDF]

, 2011
This article is made available through the Brunel Open Access Publishing Fund - Copyright @ 2011 Anokye et al.Background: Exercise referral schemes (ERS) aim to identify inactive adults in the primary care setting.
Paul Trueman, Hillsdon, M, Nana K Anokye, Anokye, Nana K, Pavey, TG, Green, C, Colin Green, Pavey, Toby G, Anokye, Nana K., Taylor, RS, Green, Colin, Hillsdon Melvyn, Taylor, Rod S., Melvyn Hillsdon, Pavey, Toby G., Trueman, P, Toby G Pavey, Anokye Nana K, Green Colin, Anokye, NK, Trueman Paul, Trueman, Paul, Rod S Taylor, Pavey Toby G, Anokye, Nana, Hillsdon, Melvyn, Taylor Rod S   +26 more
core   +1 more source

Incremental cost-effectiveness ratio by GetCheckedOnline uptake and time horizon.

, 2023
Abbreviations: GCO–GetCheckedOnline; ICER—Incremental cost-effectiveness ratio; QALY—quality-adjusted-life years; WTP—Willingness-to-pay.
Devon Haag (17458212), Wei Zhang (405), Michael A. Irvine (8582391), Jose A. De Anda (17458209), Travis Salway (6088043), Mark Gilbert (286354)   +5 more
core   +1 more source

Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies [PDF]

, 2002
As many more clinical trials collect economic information within their study design, so health economics analysts are increasingly working with patient-level data on both costs and effects.
Briggs, Andrew H, Briggs, AH, O'Brien, B.J., Blackhouse, G, Briggs, A.H., O'Brien, Bernie J, Blackhouse, G., O'Brien, BJ, Brien, Bernie J, Blackhouse, Gordon   +9 more
core   +1 more source

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China

Frontiers in Pharmacology, 2019
PurposeAgents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, become available for the treatment of Chinese patients with type 2 diabetes mellitus (T2DM).
Xingyun Hou, Xu Wan, Bin Wu
doaj   +1 more source

Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold

ClinicoEconomics and Outcomes Research, 2015
In health technology assessment (HTA) agencies where cost-effectiveness plays a role in decision-making, an incremental cost-effectiveness ratio (ICER) threshold is often used to inform reimbursement decisions. The acceptance of submissions with ICERs higher than the threshold was assessed across different agencies and across indications, in order to ...
Griffiths,Elizabeth, Hendrich,Janek, Stoddart,Samuel, Walsh,Sean   +3 more
openaire   +6 more sources

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Dermatology and Therapy, 2023
Introduction This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the ...
Jinsui Zhang, Zemin Xia, Wanjie Guo, Xiaoxiao Ren, Fang Liu, Gargi Ratnaparkhi, Amit Pagada, Subhashini Subramanian, Min Hu, Wen Chen   +9 more
doaj   +1 more source

Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.

, 2019
Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.
Frauke Becker (2836922), Denise Howel (16468), Catherine Haighton (2157001), Martin White (16466), Andrew Bryant (5704967), Terry Aspray (6194804), Luke Vale (3435356), Elaine McColl (533649), Suzanne Moffatt (16467), Sarah Lawson (6194801), Melanie Steer (6194798), Eugene M. G. Milne (2215138)   +11 more
core   +1 more source

Cost-effectiveness scatter plot.

, 2023
This study assessed the cost-effectiveness of different diabetic retinopathy (DR) screening strategies in rural regions in China by using a Markov model to make health economic evaluations.
Na Li (6550), Guanyan Li (13955389), Qingyue Gao (13955383), Shaofeng Hao (13955380), Ziyou Yuan (13955386), Shengfu Fan (13896345), Changyan Liu (9321797), Jianzhou Yang (4744092), Huilin Li (795365)   +8 more
core   +1 more source

Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage

Cost Effectiveness and Resource Allocation, 2012
In assessing the cost-effectiveness of an intervention, the interpretation and handling of uncertainties of the traditional summary measure, the Incremental Cost Effectiveness Ratio (ICER), can be problematic.
Hounton Sennen, Newlands David
doaj   +1 more source